REYKJAVIK, Iceland -- 8 April, 2024 -- Akthelia Pharmaceuticals, an innovative biopharmaceutical company committed to improving outcomes in oncology, wound healing, and inflammatory conditions through a novel immunotherapeutic approach targeting epithelial barriers, is thrilled to announce its receipt of the European Commission Seal of Excellence. This distinguished award underscores the high quality and potential impact of Akthelia's project proposals within the Horizon Europe program framework.
"We are honored to receive the European Commission's Seal of Excellence," commented Egill Masson, CEO of Akthelia Pharma, "This recognition is a significant milestone for our team, affirming the value and potential of our innovative approach to healthcare. We remain dedicated to pushing the boundaries of science to improve patient outcomes and are encouraged by this acknowledgment to continue our important work."
"We are honored to receive the European Commission's Seal of Excellence," commented Egill Masson, CEO of Akthelia Pharma, "This recognition is a significant milestone for our team, affirming the value and potential of our innovative approach to healthcare. We remain dedicated to pushing the boundaries of science to improve patient outcomes and are encouraged by this acknowledgment to continue our important work."
The Seal of Excellence award is part of the Horizon Europe program, aimed at fostering research and innovation within the EU. It signifies the European Commission's confidence in Akthelia Pharmaceuticals' projects, recommending them for consideration by other funding bodies and further promoting the integration of high-quality research initiatives across Europe. All projects with Seal of Excellence certificate have been assessed in a call for proposals under an EU funding programme and have been deemed excellent as they meet the quality requirements of the specific EU programme. These projects are judged to deserve funding and are recommended to receive support from other EU or national/regional sources.
Akthelia Pharmaceuticals looks forward to leveraging this recognition to advance its mission of developing first-in-class therapeutics that address unmet medical needs in oncology, wound healing, and inflammatory diseases. The company is committed to working collaboratively with partners and investors to bring these critical solutions to patients worldwide.
Download Akthelia's digitally signed Seal of Excellence.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals - Leading the Science of Our Surfaces™️ - is a late preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program aims to improve outcomes in cancer care through reducing the risk of chemotherapy-induced bloodstream infections, a common and severe complication in chemotherapy and immunocompromised patients, through upregulating the innate immunology in the GI tract, and thereby blocking leakage of microbiota, an established cause of these potentially fatal bloodstream infections.
CONTACTS
Egill Masson CEO egill.masson@aktheliapharma.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland